Welcome to our dedicated page for Rhelion Life Sciences news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Rhelion Life Sciences stock.
Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Rhelion Life Sciences (OTCQB: TRUFF) announced that wholly owned subsidiary Filament Health has signed a non-binding letter of intent with San Francisco-based Darmiyan to explore using Darmiyan’s FDA De Novo authorized BrainSee AI brain imaging platform in the design of potential future clinical trials of PEX010, Filament’s patented, standardized, GMP-manufactured natural psilocybin drug candidate.
The parties intend to evaluate BrainSee and Darmiyan’s “Virtual Microscope” technology for identifying, selecting and monitoring individuals with amnestic mild cognitive impairment at elevated risk of progression to Alzheimer’s disease, and to consider voxel-based quantitative imaging outputs as exploratory measures of biological change in early Alzheimer’s research involving PEX010.
Rhelion Life Sciences (OTCQB: TRUFF) appointed Samiuddin Khaja as Chief Financial Officer, effective immediately, as it continues its shift into a focused, research-led life sciences company following the acquisition of Filament Health and the launch of the Rhelion Life Sciences identity.
Khaja is an internationally designated CPA with over 15 years of global finance and accounting experience and has led finance functions for public and private companies, including in the psychedelic sector. Keith Li is stepping down as CFO after supporting Rhelion through key corporate development and the Filament acquisition and integration. Rhelion is now concentrating on pharmaceutical drug development, GMP manufacturing and regulated supply of naturally derived psychedelic drug candidates, supported by 76 issued patents, a Health Canada Dealer's Licence, FDA IND experience and a global clinical supply platform backing more than 80 clinical studies.
Rhelion Life Sciences (OTCQB: TRUFF), through its wholly owned subsidiary Filament Health, has signed a licence agreement with University Health Network (UHN) in Toronto to supply its patented, naturally derived psilocybin drug candidate PEX010 for the randomized clinical trial PSI-PARK.
According to Rhelion Life Sciences, PSI-PARK (“Evaluating the Use of Psilocybin to Treat Parkinson's Depression: A Randomized Clinical Trial”) will study psilocybin for depression in people with Parkinson’s disease. UHN sponsors the trial, with Dr. Joshua Rosenblat as principal investigator; Filament supplies PEX010 but is not responsible for trial conduct.
The company highlights Parkinson’s depression as a significant unmet need and notes prior open-label pilot data showing sustained mood improvements without serious adverse events. PEX010 supports more than 80 research studies worldwide and is produced under GMP with standardized doses from 0.5 mg to 25 mg. On April 30, 2026, Rhelion completed its acquisition of Filament, adding 76 issued patents across 15 families and consolidating PEX010 as its lead drug candidate.
Rhelion Life Sciences Corp. (CSE: RHEL, OTCQB: TRUFF, FSE: 4YX) has completed its corporate name change from Red Light Holland Corp. and changed its Canadian Securities Exchange ticker from TRIP to RHEL. Common shares will begin trading under the new name and symbol on the CSE at market open on August 7, 2026, with new CUSIP 76206T108 and ISIN CA76206T1084.
According to the company, no action is required from shareholders, and existing share and warrant certificates remain valid. The rebrand follows the acquisition of Filament Health and is intended to reflect Rhelion’s evolution into a science‑driven life sciences company focused on discovering, developing and commercializing naturally derived psychedelic medicines, supported by expanding clinical programs, intellectual property and pharmaceutical manufacturing capabilities.
Red Light Holland (OTCQB: TRUFF) reported audited results for fiscal 2026 and outlined its transition to Rhelion Life Sciences following the acquisition of Filament Health. Revenue was $4.195M versus $4.944M in 2025, with gross profit of $1.591M and a larger EBITDA loss of $6.754M. Cash declined to $8.471M and total assets to $14.570M.
The Filament deal created a vertically integrated psychedelic drug platform with 76 issued patents, GMP manufacturing, a Health Canada Level 8 Dealer's Licence and botanical psilocybin candidate PEX010, which has completed Phase I and is Phase II-ready. The company supports more than 80 clinical studies and plans a corporate rebrand to Rhelion Life Sciences effective August 4, 2026, while keeping existing stock symbols.
Red Light sold SR Wholesale for €150,000, suspended shiitake production at AEM New Brunswick, is exploring options for MiniChamp and may monetize AEM Ontario farmland appraised at CAD$2M as it refocuses on pharmaceutical-grade psychedelic development, licensing and strategic partnerships.
Red Light Holland (OTCQB: TRUFF) will change its corporate name to Rhelion Life Sciences Corp, pending CSE approval, to reflect its evolution into a focused, science-driven psychedelic drug discovery and development platform following the completed acquisition of Filament Health.
Under the Rhelion brand, the company plans to leverage Filament’s patented, naturally derived psilocybin drug candidate PEX010, its clinical and compassionate use network, and expanded pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities. Filament recently added a 0.5 mg dose to existing 1, 5 and 25 mg strengths, enabling standardized dosing from microdosing to full therapeutic levels.
According to the company, PEX010 is protected by a broad patent portfolio, has a demonstrated 36‑month shelf life, and has been supplied to more than 80 academic and philanthropic research studies worldwide, supporting its strategy as a clinical and research-led psychedelic enterprise.
Red Light Holland (OTCQB: TRUFF) announced that Filament Health has completed a shipment of its botanical psilocybin drug candidate PEX010 into the European Union, released via a European Qualified Person, to supply multiple independent investigator-led studies, including projects linked to Nantes University Hospital and Region Stockholm in collaboration with Karolinska Institutet.
According to Red Light Holland, Filament only supplies PEX010 and is not running these trials. PEX010 now supports over 80 academic and philanthropic studies worldwide, backed by a portfolio of 76 issued patents across 13 families acquired when Red Light Holland closed its Filament transaction on April 30, 2026.
Red Light Holland (OTCQB:TRUFF) announced that Filament Health has begun its largest-ever manufacturing run of PEX010, a standardized, patented natural psilocybin drug candidate. The run adds a new 0.5 mg dose to existing 1, 5 and 25 mg strengths, creating a 0.5–25 mg standardized range from a single, consistent drug product.
PEX010 is protected by an international patent portfolio, has a demonstrated 36‑month shelf life, and has been supplied to 80+ research studies worldwide. The new low dose targets real-world microdosing patterns and aims to support controlled clinical research. Red Light completed its acquisition of Filament and its 76 issued patents on April 30, 2026.
Red Light Holland (OTCQB: TRUFF) announced that wholly owned subsidiary Filament Health signed an agreement with ARQ National Psychotrauma Centre in the Netherlands to supply its patented botanical psilocybin drug candidate PEX010 for a pilot feasibility study in military veterans with posttraumatic stress disorder (PTSD).
PEX010 will serve as the investigational drug product. According to Red Light Holland, PEX010 has been supplied to more than 80 academic and clinical studies worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.
Red Light Holland (OTCQB:TRUFF) reported that joint venture partner Magdalena Biosciences achieved positive preclinical results with a whole-leaf coca extract, its prescription drug candidate for post-GLP-1 weight loss management.
In a 20-day mouse study on a high-fat diet, the extract prevented weight gain without reducing food intake or increasing activity, supporting further development under FDA Botanical Guidance.